Saturday 17 October 2026 Export INMB’s income statement to Excel — free account

INmune Bio, Inc.

INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024. In the quarter to June 2026, revenue grew 8.70%, EPS grew 95.2% and free cash flow grew 55.4%, each against the same quarter a year earlier.

1.57 0.08 −4.85%

Follow INMB

Alert me

Market cap: $45.8M
P/E: 0.0×
Fwd P/E: −1.8×
Dividend yield: —
F-score: 4/9
Altman Z: −10.46
Beneish M: −3.67
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 7.37%

Capital & Financial Ratios $m

Market Cap 45.80

Revenue 0.14

Net Income (18.42)

Free Cash Flow (16.43)

Net Debt (18.41)

Current Ratio 4.04

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.79)

P/S ratio 310.73

P/B ratio 2.06

Past 5Y EPS Growth —

This Y EPS Growth 70.43%

Next Y EPS Growth (40.00%)

Next Y revenue growth 18,980.00%

Next 5Y EPS Growth 25.15%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 15.54%

10-year low 10-year high

P/B against its own 10 years 24.11%

10-year low 10-year high

EV/Sales against its own 10 years 24.27%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	36	21	25	18
Receivables	2	1	5	5
Inventory	—	—	—	—
Other	—	—	—	—
	40	23	30	24

	2023	2024	2025	Q'26
Payables	8	7	8	5
ST’ Debt	10	—	—	—
Other	0	1	—	—
	18	7	8	6

Compound Annual Growth %

	10y	5y	3y
Sales	—	35.37%	(48.87%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(9.50%)	(26.85%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	—	—	—	0
’24	0	—	—	—	0
’23	0	0	0	0	0
’22	0	0	0	0	0
’21	0	—	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(7)	(7)	(5)	(3)	(23)
’24	(7)	(8)	(7)	(11)	(33)
’23	(1)	(3)	(4)	(3)	(12)
’22	(9)	(5)	(3)	(6)	(23)
’21	(5)	(6)	(8)	(10)	(29)
’20	(1)	(2)	(4)	(2)	(9)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(4)	—	—	—
’25	(7)	(8)	(6)	(3)	(24)
’24	(7)	(8)	(7)	(11)	(33)
’23	(1)	(3)	(4)	(3)	(12)
’22	(9)	(5)	(3)	(6)	(23)
’21	(5)	(21)	(8)	(10)	(44)
’20	(1)	(2)	(4)	(2)	(9)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.20)	(0.05)	—	—	—
’25	(0.43)	(1.05)	(0.24)	(0.18)	(1.86)
’24	(0.61)	(0.50)	(0.60)	(0.40)	(2.11)
’23	(0.36)	(0.36)	(0.48)	(0.47)	(1.67)
’22	(0.39)	(0.38)	(0.43)	(0.32)	(1.52)
’21	(0.32)	(0.44)	(0.55)	(0.55)	(1.88)
’20	(0.19)	(0.20)	(0.36)	(0.24)	(1.01)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	3.51	2.20	9.23	4.63	5.87	4.32	1.38	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	11.50	24.42	30.37	11.78	11.78	14.74	11.64
People
People	Employees	—	2	3	4	5	10	10	17	22	21
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.02	0.04	0.01	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	0	0	0	0	0	0
	Gross margin, %	—	—	—	—	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	0	(1)	(12)	(8)	(12)	(30)	(27)	(30)	(42)	(46)
	EBT margin, %	0.00	0.00	0.00	0.00	(109,990.91)	(16,762.43)	(7,299.20)	(19,360.00)	(300,685.71)	(91,866.00)
	Net income	0	(1)	(12)	(8)	(12)	(30)	(27)	(30)	(42)	(46)
	Depreciation	—	—	—	—	—	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.01	0.02	0.01	0.00	0.00
	Earnings	(0.02)	(0.13)	(1.43)	(0.75)	(1.01)	(1.88)	(1.52)	(1.67)	(2.11)	(1.86)
	Cash flow	(0.03)	(0.12)	(0.24)	(0.52)	(0.75)	(1.77)	(1.27)	(0.67)	(1.67)	(0.91)
	Capex	0.00	(0.02)	0.00	0.00	0.00	(0.93)	0.00	0.00	0.00	(0.04)
	Free cash flow	(0.03)	(0.13)	(0.24)	(0.52)	(0.75)	(2.70)	(1.27)	(0.67)	(1.67)	(0.95)
	Book value	(0.01)	2.76	1.91	2.30	3.23	4.97	3.35	2.08	1.61	0.95
	Shares, m	11	7	9	10	12	16	18	18	20	25
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	0.00	857.41	321.63	1,301.59	710.98	286.09
	P/B	—	—	—	—	5.33	2.05	2.00	5.40	2.90	1.64
	EV/Sales	—	—	—	—	0.00	543.28	221.48	1,149.65	588.45	138.83
	EV/FCF	—	—	—	—	(20.64)	(3.66)	(3.65)	(14.87)	(2.31)	(0.79)
Cash, $m
Cash, $m	Operating cash flow	0	(1)	(2)	(5)	(9)	(29)	(23)	(12)	(33)	(23)
	Capex	—	0	—	—	—	(15)	—	—	—	(1)
	Free cash flow	0	(1)	(2)	(5)	(9)	(44)	(23)	(12)	(33)	(24)
Balance, $m
Balance, $m	Working capital	0	2	0	7	22	78	54	21	15	21
	Total debt	0	—	—	0	0	15	15	10	—	—
	Net debt	0	(1)	0	(7)	(22)	(60)	(37)	(26)	(21)	(25)
	Shareholders’ equity	0	18	17	24	39	80	60	37	32	24
Returns, %
Returns, %	ROA	(2.94)	(8.82)	(69.54)	(36.71)	(37.16)	(43.16)	(30.04)	(43.24)	(87.16)	(127.75)
	ROIC	0.00	(3.67)	(47.54)	(28.88)	(45.10)	(91.35)	(71.62)	(162.87)	(238.53)	0.00
	ROE	(3.09)	(9.26)	(71.82)	(38.25)	(38.80)	(51.00)	(38.91)	(61.59)	(121.21)	(165.16)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KLRS Kalaris Therapeutics Inc.	$47.8M	— (loss-making)	—	—	n/m	+11.91% (above 0%: growing)	0.00%	0.00%	Compare
IBIO iBio, Inc.	$47.6M	— (loss-making)	— (loss-making)	+100.00% (above 0%: growing)	n/m	−35.33% (below 0%: shrinking)	100.00%	0.00%	Compare
CLNN Clene Inc.	$47.0M	— (loss-making)	— (loss-making)	+233.33% (above 0%: growing)	n/m	+45.43% (above 0%: growing)	60.00%	(5,941.11%)	Compare
TVGN Tevogen Inc.	$46.1M	— (loss-making)	—	—	n/m	+5.78% (above 0%: growing)	—	0.00%	Compare
INMB INmune Bio, Inc.	$45.8M	— (loss-making)	— (loss-making)	+8.70% (above 0%: growing)	n/m	+55.39% (above 0%: growing)	100.00%	0.00%
IMA ImageneBio, Inc.	$45.7M	— (loss-making)	— (loss-making)	−60.08% (below 0%: shrinking)	n/m	+23.76% (above 0%: growing)	100.00%	0.00%	Compare
SER Serina Therapeutics, Inc.	$45.5M	— (loss-making)	— (loss-making)	+2,500.00% (above 0%: growing)	n/m	−76.82% (below 0%: shrinking)	100.00%	0.00%	Compare
ANVS Annovis Bio, Inc.	$44.8M	— (loss-making)	—	—	n/m	−329.18% (below 0%: shrinking)	—	0.00%	Compare
ALDX Aldeyra Therapeutics, Inc.	$44.5M	— (loss-making)	—	—	n/m	+46.09% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$45.9M	—	—	+166.67%	—	+8.85%	80.00%	0.00%

All 614 Biotechnology stocks →

INmune Bio, Inc. (INMB) key facts

Strength: INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024.
INmune Bio, Inc. (INMB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, INMB traded at $1.57, a market capitalization of $45.8 million.
Return on equity was −165.2% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −10.46 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.